Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hypertension
Tekturna®, first approved direct renin inhibitor, effectively lowers high blood pressure in elderly patients
November 26th, 2008
New clinical data presented today show the first approved direct renin inhibitor Tekturna® (aliskiren) provides effective blood pressure reductions in patients with high blood pressure aged 65 and older. In the AGELESS study, Tekturna lowered systolic blood pressure by an additional 2.3 mmHg in patients aged 65 and over, compared to the ACE inhibitor ramipril. Results from the AGELESS study were presented at the American Heart Association (AHA) Scientific Sessions 2008. Almost seventy percent of people over age 60 have high blood pressure and it remains uncontrolled in more than 60 percent of hypertensive adults over age 60. Even adults who do not have high blood...
Source: Vaccine Weekly (2008-11-26)
|
